HHS Peptide Policy: BPC-157, TB-500 and 4 More Cleared for Compounding

HHS Just Told the FDA to Look the Other Way on Six Peptides

On Wednesday, October 28, the Department of Health and Human Services put out an "enforcement discretion" policy for six peptides: BPC-157, TB-500, Semax, Epithalon (spelled "epitalon" in the notice), KPV and MOTS-c. In plain English: HHS will not go after compounding pharmacies that make them, even though none of the six is FDA approved.

This is a big deal. It is also messier than the headlines make it sound. Let's go through what is actually in it. 🧪

What the policy actually does

Per NBC News, HHS says it will not take legal action against compounding pharmacies that make these six peptides. They are not yet on the FDA's list of bulk ingredients pharmacies are allowed to use, so this is a stopgap while a formal rule change is pending.

The policy is built around conditions, and they are not trivial. Legal analyses of the notice from two law firms describe the same core requirements:

• The original manufacturer of the raw ingredient must be registered with the FDA and follow current good manufacturing practice, with the facility showing up on the certificate of analysis.
• The ingredient needs real analytical testing (identity, purity, potency, impurities, contaminants), not a generic certificate.
• Products must be patient-specific prescriptions. No office stock, no wholesale distribution.
• Each product may contain only one of the listed peptides. Both law-firm write-ups say that rules out a BPC-157 plus TB-500 "Wolverine stack" in one vial. Scientific American reported the opposite on combinations, so read the notice itself before relying on that point.
• Pharmacies have to report serious adverse events and quality problems.

AP adds that pharmacies must verify the chemical identity of the peptides and collect side-effect information. NBC notes that side-effect reporting was not previously required.

The coverage also names who it applies to: state-licensed 503A pharmacies, federal facilities and licensed physicians. It does not cover 503B outsourcing facilities.

Where this came from

In 2023, AP reports, the FDA added more than a dozen peptides, including BPC-157 and TB-500, to its list of substances that should not be compounded, citing risks including allergic reactions, kidney damage and tumor growth.

Then, per BioSpace and NCPA, the FDA's Pharmacy Compounding Advisory Committee met July 23 and 24, 2026 and voted to recommend adding these six peptides to the compounding bulks list. It voted against a seventh, emideltide (also called DSIP). NBC reports the vote was narrow.

Normally the next step is a proposed rule, public comment and a final rule, which NBC says can take several months. Law-firm analyses put the formal bulks-list process at 12 to 24 months. The enforcement policy is the bridge in the meantime.

The part the FDA scientists did not love

AP, citing six people familiar with the policy, reports that most FDA scientific staff opposed it and had limited input in drafting it. AP says HHS originally wanted the FDA to issue a regulation adding the peptides to the compounding list, FDA officials said staff had major safety concerns and would not support that, and HHS switched to non-enforcement instead. AP also says FDA staff did help with technical details, including safety guardrails.

Critics are loud. The pharmaceutical trade group's general counsel said it was "deeply concerning that HHS is telling the FDA they should ignore the law." The AMA's president said the peptides have "not undergone the rigorous testing required of FDA-approved drugs." Scientific American says there is scant human evidence behind them.

That last point is fair, and we will not pretend otherwise. Most of the case for these peptides still rests on animal and preclinical work plus a lot of community experience. Permission to compound is not proof of efficacy. Those are different things.

What it means for the research community

For years, people who wanted these compounds had two choices: ask a doctor who had no legal way to prescribe them, or buy research-grade material online. AP notes that many people get peptides as vials ordered from chemical manufacturers abroad, often labeled for research use only. Kennedy's stated argument, per AP, is that people are turning to the gray market and compounding gives them another route.

Here is our take. A legal pharmacy route is good for people who want a prescription and a medical relationship, and it is a real shift that these compounds are being discussed at the federal level at all. But a pharmacy channel has constraints: one peptide per product, a prescription, state board rules, and whatever a pharmacy decides to stock. Law-firm analyses are explicit that the notice does not change the legal position of research-use-only products. The research community's knowledge base did not come from a federal notice, and it is not going anywhere.

Also worth knowing: the notice is described as non-binding and revisable. HHS says it may revisit the policy if safety or quality problems emerge, per Scientific American. Policy that can be pulled back is not the same as policy that is settled.

What it does not do

Straight from the legal write-ups:

• It does not add these peptides to the compounding bulks list. Only formal rulemaking does that.
• It does not make any of the six FDA approved.
• It does not override state pharmacy boards.
• It does not authorize importation or general commercial distribution.
• It does not cover other peptides, even popular ones.

The profile pages are the place to see how the evidence breaks down for each one. If you want to compare two of them, try BPC-157 vs TB-500 or Epithalon vs MOTS-c, or browse the full peptide database.

The comment window

According to two law-firm analyses, the notice is scheduled for Federal Register publication on October 30 under docket HHS-OASH-2026-0496, with a comment period of two weeks after publication. We could not confirm the final dates from the Federal Register text itself, so check the docket directly before you plan around the deadline. If you have informed, factual input on these peptides, a public docket is where it counts.

Bottom line

Six peptides that were stuck in regulatory limbo now have a temporary pathway through licensed compounding pharmacies, with real manufacturing and reporting conditions attached. The FDA's own staff reportedly did not back the approach, the evidence base is still thin, and the policy can change. Keep your expectations realistic and read the actual notice.

This post is educational, not medical advice.

Sources

• NBC News: RFK Jr. takes shortcut to make some unapproved peptides available
• AP via PBS NewsHour: FDA scientists opposed the Trump administration's move to ease peptides access
• BioSpace: HHS clears compounding pharmacies to manufacture 6 unapproved peptides
• NCPA: FDA grants enforcement discretion for compounding six peptides
• Frier Levitt: HHS Peptide Compounding Enforcement Discretion Policy
• Luma Lex Law: HHS Opens a Temporary Door for Peptides
• Scientific American: RFK Jr. loosens restrictions for six popular peptides